Three things to know:
1. The FDA approved the cervical artificial disc in 2012. Globus Medical designed the disc for reconstruction and motion perseveration at the operated disc level.
2. Globus Medical published a long term, seven-year clinical trial in the International Journal of Spine Surgery outlining the success of the Secure-C compared to traditional anterior cervical discectomy and fusion.
3. At seven-year post-operative follow-up, patients treated with Secure-C exhibited the following results compared to patients treated with ACDF:
• Statistically superior composite protocol-specified overall success results (86.3 percent vs. 70 percent)
• Statistically superior composite FDA-defined overall success results (79.2 percent vs. 63.6 percent)
• Greater percentage of patients with at least 25 percent improvement in Neck Disability Index (90.4 percent vs. 86 percent)
• Lower rate of subsequent surgery at the original treated level (4.2 percent vs. 15.3 percent)
• Lower rate of adjacent level surgery (4.2 percent vs. 16 percent)
More articles on devices and implants:
Nextech acquires EMR solution for orthopedic practices: 3 details
How China-US tariff tension affects orthopedic companies; Moody’s thinks they’ll adapt
3 things to know about AxioMed
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
